Thryv (NASDAQ:THRY – Get Free Report) will announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($2.53) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Thryv Price Performance
Shares of THRY stock opened at $14.87 on Tuesday. The company has a debt-to-equity ratio of 1.58, a current ratio of 1.14 and a quick ratio of 1.14. The company has a market capitalization of $539.83 million, a P/E ratio of -1.91 and a beta of 0.85. The company’s 50-day simple moving average is $17.40 and its two-hundred day simple moving average is $18.79. Thryv has a one year low of $13.74 and a one year high of $26.42.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on THRY shares. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Thryv in a research note on Wednesday, October 30th. Craig Hallum initiated coverage on shares of Thryv in a research note on Wednesday, October 2nd. They set a “buy” rating and a $25.00 price objective on the stock.
Thryv Company Profile
Thryv Holdings, Inc provides digital marketing solutions and cloud-based tools to the small-to-medium sized businesses in the United States. It operates through four segments: Thryv U.S. Marketing Services, Thryv U.S. SaaS, Thryv International Marketing Services, and Thryv International SaaS. The company provides print yellow pages, internet yellow pages, and search engine marketing; and other digital media solutions, such as online display and social advertising, online presence and video, and search engine optimization tools.
See Also
- Five stocks we like better than Thryv
- What is a Dividend King?
- Intel: Is Now the Time to Be Brave?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Why Invest in 5G? How to Invest in 5G Stocks
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Thryv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thryv and related companies with MarketBeat.com's FREE daily email newsletter.